WallStreetZenWallStreetZen

NASDAQ: LVTX
Lava Therapeutics Nv Stock

$1.64+0.02 (+1.23%)
Updated Mar 29, 2023
LVTX Price
$1.64
Fair Value Price
$4.02
Market Cap
$43.11M
52 Week Low
$1.56
52 Week High
$7.38
P/E
-1.19x
P/B
0.46x
P/S
6.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.31M
Earnings
-$28.69M
Gross Margin
100%
Operating Margin
-178.36%
Profit Margin
-182%
Debt to Equity
0.62
Operating Cash Flow
-$39M
Beta
0.1
Next Earnings
May 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A

LVTX Overview

LAVA Therapeutics N.V. offers Gammabody platform, a portfolio of novel bispecific antibodies that engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. The company's lead clinical-stage candidates are LAVA-051, in Phase 1/2a clinical trials for blood cancers (chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia), and LAVA-1207, in Phase 1/2a clinical trials for metastatic castration-resistant prostate cancer. LAVA Therapeutics was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LVTX ($1.64) is undervalued by 59.23% relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LVTX ($1.64) is significantly undervalued by 59.23% relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LVTX due diligence checks available for Premium users.

Be the first to know about important LVTX news, forecast changes, insider trades & much more!

LVTX News

Valuation

LVTX fair value

Fair Value of LVTX stock based on Discounted Cash Flow (DCF)
Price
$1.64
Fair Value
$4.02
Undervalued by
59.23%
LVTX ($1.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LVTX ($1.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LVTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.19x
Industry
18.17x
Market
21.81x

LVTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.92x
LVTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LVTX's financial health

Profit margin

Revenue
$15.3M
Net Income
$997.0k
Profit Margin
6.5%
LVTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LVTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$149.9M
Liabilities
$57.2M
Debt to equity
0.62
LVTX's short-term assets ($149.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LVTX's short-term assets ($149.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.3M
Investing
$6.6M
Financing
-$7.0k
LVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LVTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
LVTX$43.11M+1.23%-1.19x0.46x
GNPX$43.22M-3.23%-1.88x1.57x
DYAI$42.93M-0.67%-4.38x3.87x
AVRO$42.77M-7.62%-0.40x0.57x
SYBX$42.67M+2.94%-0.68x0.52x

Lava Therapeutics Nv Stock FAQ

What is Lava Therapeutics Nv's quote symbol?

NASDAQ: LVTX) Lava Therapeutics Nv trades on the NASDAQ under the ticker symbol LVTX. Lava Therapeutics Nv stock quotes can also be displayed as NASDAQ: LVTX.

If you're new to stock investing, here's how to buy Lava Therapeutics Nv stock.

What is the 52 week high and low for Lava Therapeutics Nv (NASDAQ: LVTX)?

(NASDAQ: LVTX) Lava Therapeutics Nv's 52-week high was $7.38, and its 52-week low was $1.56. It is currently -77.78% from its 52-week high and 5.13% from its 52-week low.

How much is Lava Therapeutics Nv stock worth today?

(NASDAQ: LVTX) Lava Therapeutics Nv currently has 26,289,087 outstanding shares. With Lava Therapeutics Nv stock trading at $1.64 per share, the total value of Lava Therapeutics Nv stock (market capitalization) is $43.11M.

Lava Therapeutics Nv stock was originally listed at a price of $14.30 in Mar 25, 2021. If you had invested in Lava Therapeutics Nv stock at $14.30, your return over the last 2 years would have been -88.53%, for an annualized return of -66.13% (not including any dividends or dividend reinvestments).

How much is Lava Therapeutics Nv's stock price per share?

(NASDAQ: LVTX) Lava Therapeutics Nv stock price per share is $1.64 today (as of Mar 29, 2023).

What is Lava Therapeutics Nv's Market Cap?

(NASDAQ: LVTX) Lava Therapeutics Nv's market cap is $43.11M, as of Mar 31, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lava Therapeutics Nv's market cap is calculated by multiplying LVTX's current stock price of $1.64 by LVTX's total outstanding shares of 26,289,087.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.